Plain-English translation of NCT03937635 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a monoclonal antibody medication, can improve outcomes when combined with two standard myeloma drugs ( and ). Researchers want to find out if adding this new medication helps people with early-stage, high-risk myeloma live longer and stay healthier. Half of the participants will receive the three-drug combination, while the other half will receive just the two standard drugs.
Smoldering myeloma is an early form of blood cancer that often progresses to active myeloma within a few years, especially in high-risk patients. This trial is trying to determine whether the medication can delay or prevent this progression and help people live longer.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic regularly to receive treatment over approximately 2 years. You will receive either the combination of three medications or two medications, given by mouth and by IV infusion on a set schedule. You'll have blood and urine tests monthly, complete quality-of-life surveys, and be monitored for side effects throughout the study and for 6 months after treatment ends.
AI-generated summary from trial data · Aug 31, 2026 · Not medical advice
United States